Earlier this week, on Thursday 8th November, Sandoz, a unit of Novartis said that it would recall a single lot of Losartan tablets. The pharmaceutical company is making this recall after it found traces of a probable carcinogen in the blood pressure drug.
Zhejiang Huahai Pharmaceutical Co. Ltd., a Chinese company made this drug. In October, the European Medicines Agency kept the company under high supervision. This was after the agency found that Valsartan, a blood pressure drug contained a probable carcinogen.
The agency also tested and reviewed other ‘sartan’ medicines which included candesartan, valsartan, irbesartan, olmesartan, and losartan. This was testing was done after very low levels of a carcinogen was found in losartan which made by Hetero Labs in India.
Sandoz did not receive any reports of adverse effects related to this recalled lot.